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Gprotein-biased agonists of the µ-opioid
receptor have been hypothesized to be
an improved class of opioid analgesics
Early studies in the β-arrestin2-knockout
mouse that suggested a separation be-
tween the signaling mediating analgesia
versus side effects have not been
reproduced, and a ‘G protein-biased’
mutant MOPr mouse does not support
the original proposal.
There is now evidence for a G protein-
dependent signal mediating deleteriousG protein-biased agonists of the μ-opioid receptor (MOPr) have been proposed
as an improved class of opioid analgesics. Recent studies have been unable to
reproduce the original experiments in the β-arrestin2-knockout mouse that led
to this proposal, and alternative genetic models do not support the G protein-
biased MOPr agonist hypothesis. Furthermore, assessment of putatively
biased ligands has been confounded by several factors, including assay
amplification. As such, the extent to which current lead compounds represent
mechanistically novel, extremely G protein-biased agonists is in question, as
is the underlying assumption that β-arrestin2 mediates deleterious opioid
effects. Addressing these current challenges represents a pressing issue to
successfully advance drug development at this receptor and improve upon
current opioid analgesics.opioid effects.
The previously observed G protein bias
of many recently developed MOPr ago-
nists has been confounded by assay
amplification. Such ligands may in fact
be unbiased, with low intrinsic efficacy.
Current evidence does not support the
proposal that G protein-biased agonism
at the MOPr will provide substantially im-
proved therapeutic profiles.
Low intrinsic efficacy represents an
alternative mechanism by which novel
opioids may display wider therapeutic
windows.
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G protein-biased agonists (see Glossary) of the μ-opioid receptor (MOPr) have been widely
proposed to be a novel, substantially improved class of analgesics [1,2]. The prototypical such
agonist, oliceridine (TRV130), has proceeded to Phase III clinical trials [3], and was recently
approved in the USA for use in acute pain. Existing, clinically approved opioid analgesics, such
as morphine, oxycodone, and fentanyl, are MOPr agonists that provide pain relief that is
unmatched by other drug classes. Current opioids have an array of adverse effects, including re-
spiratory depression, constipation, and euphoria, as well as inducing tolerance and dependence
over time. These important limitations of opioid analgesics have all been proposed to be ad-
dressed by G protein-biased MOPr agonists (Box 1). However, recent results have brought
into question the hypothesis that underpins the proposedmechanism of action of this anticipated
new drug class, that β-arrestin2 mediates deleterious opioid effects. In addition, there is evi-
dence that challenges both the extent of the G protein bias of lead compounds and the extent
to which such compounds are likely to represent improved analgesics.
G Protein Signaling in Respiratory Depression and Constipation Induced by
Opioids
The target of opioid analgesics, MOPr, is a G protein coupled receptor (GPCR) that signals
predominantly through activation of the Gαi/o and βγ proteins. MOPr activation alters neuronal
function through well-established G protein signalingmechanisms, including postsynaptic activa-
tion of G protein coupled inwardly rectifying potassium channels (GIRK), causing hyper-
polarization and inhibition of neurons [4]. Presynaptic inhibition of neurotransmission also
occurs through G protein signaling of MOPr, predominantly via the inhibition of voltage-gated
calcium channels (VGCC) [5]. G protein signaling of the MOPr can be negatively regulated
via a system of intracellular C-terminal phosphorylation by various kinases, and β-arrestin binding
common to most GPCRs. In addition to negative regulation of G protein signaling, the recruit-
ment of β-arrestin to MOPr has been proposed to transduce a G protein-independent signalTrends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.tips.2020.09.009 1
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Trends in Pharmacological Sciences[1,2]. To date, however, the nature of this putative signal has not been described and it remains
unclear how β-arrestin signaling mediates discrete physiological effects.
Central to the proposed benefit of putatively G protein-biased MOPr agonists [6–9] is the hypoth-
esis that MOPr/β-arrestin interactionsmediate opioid-induced respiratory depression and consti-
pation [1], based on results obtained using the β-arrestin2-knockout mouse [10]. Opioid-induced
respiratory depression is themajor cause of overdose death, andmultiple genetic knockout stud-
ies have shown that it results from activation of MOPr rather than δ- or κ-opioid receptor subtypes
(DOPr and KOPr) or the opioid-related nociceptin/orphanin FQ receptor (NOPr) [7,11,12], as
does inhibition of gastrointestinal transit [13].
Expression of MOPr is abundant throughout the respiratory network of the brainstem [14]. Local
removal of MOPr via viral Cre delivery from either the preBötzinger (preBötC) neurons or
Kölliker-Fuse (KF) neurons, regions critical in respiratory control, substantially reduced the ef-
fect of morphine on respiratory rate in mice [15]. A similar study confirmed this result, as well as
reporting the abolition of both morphine- and fentanyl-induced respiratory depression following
simultaneous MOPr deletion from both preBötC and KF [16], demonstrating the necessity of
MOPr expression within these areas for opioid-induced respiratory depression.
There is now significant evidence that MOPr activation in these nuclei, as is established exten-
sively throughout the nervous system, inhibits neuronal activity via G protein signaling. The
preBötC has been characterized as a site critical for opioid-induced respiratory depression
[17]. Morphine effects on respiratory rate have been defined via pharmacological ion channel
modulation and genetic knockout to occur at least partially via MOPr-induced GIRK activation
in neurons of this nucleus [18]. A presynaptic mechanism for opioid effects on preBötC activity,
via VGCC inhibition, has also been suggested from electrophysiological experiments [19].
Neurons of the KF, similar to the preBötC, are hyperpolarized via MOPr activation of
GIRK, suppressing inspiratory drive [20], while local antagonism of MOPr within the KF partially
reversed the respiratory changes induced by systemic fentanyl application [21].
These results, demonstrating that opioid-induced respiratory depression occurs substantially via G
protein signaling, are difficult to reconcile with the hypothesis that the respiratory depressant effects
of morphine are β-arrestin dependent (Box 1) [1]. This hypothesis was formed after the initial report
that morphine-induced respiratory depression was greatly attenuated in β-arrestin2-knockout
mice [10]. However, subsequent experiments in three independent laboratories failed to observe
any effect of this genotype on morphine- or fentanyl-induced respiratory depression [22] (Box 2).
Global β-arrestin2 knockout will affect all systems regulated by this ubiquitously expressed protein.
A recently developed genetic model, more selective for opioid function, used mice expressing a
modified MOPr, in which C-terminal serine and threonine phosphorylation sites were mutated to
alanine (11S/T-A mice) [23], thereby preventing both phosphorylation and β-arrestin binding [24].
Critically, both morphine and fentanyl depressed respiration in 11S/T-A mice [23], implying,
together with the lack of a β-arrestin2-knockout phenotype, that MOPr/β-arrestin interactions
are not essential for opioid-induced respiratory depression.
Opioid-induced constipation is mainly mediated by MOPr expressed peripherally in the enteric
nervous system. Key research in human intestine showed that opioids act to inhibit neuromuscu-
lar transmission, causing an increase in muscle tone and a decrease in propulsive motility [25].
Following β-arrestin2-knockout mouse studies [10], the involvement of β-arrestin2-mediated sig-
naling in the gastrointestinal actions of opioids was proposed [1]. More recent work has again,2 Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx
Glossary
129/SvJ, C57BL/6 strains: inbred
laboratory mouse substrains. Each
mouse within a given substrain is
genetically identical to another. Mixed
background animals are derived from
multiple strains and share characteristics
of each.
β-arrestin1 and 2 (arrestin2 and 3):
membrane receptor-binding family of
proteins with ubiquitous expression and
scaffolding functions. β-arrestin1 and 2
bind MOPr and mediate receptor
internalization, although MOPr agonists
recruit β-arrestin2 more effectively than
they do β-arrestin1.
μ-opioid receptor (MOPr): GPCR
expressed in the nervous system that is
the target of opioid analgesics.
Biased agonist: activates one
signaling pathway downstream of a
receptor more efficiently than it activates
another, discrete signaling pathway of
the same receptor. Biased agonism is
relative and considered in comparison to
reference ligands.
DAMGO: [D-Ala2, N-Me-Phe4, Gly5-ol]-
enkephalin, a MOPr-selective analog of
the endogenous opioid Met-enkephalin,
which is a high efficacy reference
agonist.
G protein coupled inwardly rectifying
potassium channel (GIRK): activated
by Gβγ subunits following activation of
Gi/o coupled receptors, such as MOPr,
hyperpolarizing neurons.
G protein coupled receptors
(GPCRs): seven-transmembrane
proteins that signal to cognate G
proteins throughout the body
Intrinsic efficacy: ability of a ligand to
activate a target, in this case a GPCR, as
distinct from affinity. True antagonists
have no efficacy but substantial affinity.
Biased agonists may have low intrinsic
efficacy in one signaling pathway, but
high efficacy in another.
Kölliker-Fuse (KF) neurons: part of
the parabrachial nuclei and contribute to
opioid-induced respiratory depression.
PreBötzinger (preBötC) neurons:
located in the ventral respiratory group of
the medulla of the brainstem; is essential
for the generation of the respiratory
rhythm, and is involved in opioid-
induced respiratory depression.
Therapeutic window: preclinical or
clinical separation in compound potency
for desired drug effect (e.g., analgesia)
from side effects (e.g., respiratory
depression).
Trends in Pharmacological Sciencesconversely, observed persistent morphine- and fentanyl-induced constipation in both β-arrestin2-
knockout [22,26] and 11S/T-A [23] mice. In the enteric nervous system of various species, opioids
induce neuronal hyperpolarization and reduced neuronal excitability, as well as presynaptic inhibi-
tion of neurotransmitter release [27–29], an effect prevented by pretreatment with pertussis toxin
[30]. Therefore, it is well demonstrated that opioid-induced constipation, similar to respiratory
depression, is mediated by G protein signaling, including activation of GIRK and VGCC inhibition,
without any evidence for the hypothesized β-arrestin-mediated signaling. Thus, it is difficult to
reconcile this recent evidence with the hypothesis that G protein-biased MOPr agonists, which
stimulate signaling through G proteins while sparing β-arrestin recruitment, will be safer than
unbiased agonists with regard to respiratory depression and constipation.
Opioid-Induced Analgesia, Tolerance, and Dependence
G protein-biased MOPr agonists were further proposed to induce enhanced analgesia without
tolerance [1], as well as resulting in less dependence with reduced rewarding effects [2]. Currently
used opioids, such as the prototypical morphine, produce robust analgesia throughMOPr, rather
than DOPr, KOPr, or NOPr, activation [13].
Acute opioid antinociception is primarily centrally mediated, as recently shown through condi-
tional knock out of MOPr from peripheral neurons [31,32], occurring through MOPr activation
at multiple central nervous system sites. MOPr activation within the periaqueductal gray of the
brainstem disinhibits a descending, endogenous analgesic pathway that suppresses ascending
nociceptive sensation [33]. Additionally, activation of MOPr within pre- and postsynaptic sites of
the dorsal horn directly inhibits nociception [34]. G protein-signaling mechanisms mediate MOPr
agonist effects at these sites, including GIRK activation [35,36] and VGCC inhibition [37].
Substantial and protracted efforts to develop G protein-biased MOPr agonists were spurred by
mouse genotype studies. Global knock out of β-arrestin2 in mice was observed to greatly en-
hance the acute antinociception induced by morphine [38], but not by fentanyl, methadone, or
etorphine [39]. Remarkably, tolerance to the hotplate antinociceptive effect of morphine was re-
ported not to develop in these mice [40]. This effect was again ligand specific, with no difference
in the development of antinociceptive tolerance to oxycodone, methadone, or fentanyl between
wild-type and knockout mice [41]. More recent work has observed no effect of β-arrestin2 knock-
out on either acute antinociception in response to morphine, oxycodone, or fentanyl, or to the
subsequent development of tolerance to these drugs following prolonged administration [42]
(Box 2).
The 11/ST-Amutantmouse,more selective for MOPr function than the globalβ-arrestin2 knockout,
is a less confounded model of the role of the C-terminal phosphorylation and β-arrestin-binding
system in acute antinociception and tolerance development. Morphine and fentanyl acute
antinociceptive responses were enhanced, and tolerance to this effect developed to a reduced
extent, in 11S/T-Amice comparedwith wild-typemice [23]. Knock out of individual G protein recep-
tor kinase (GRK) subtypes does not substantially alter acute or chronic opioid antinociception,
whereas homozygous knock out of a subtype crucial for MOPr regulation, GRK2, is embryonically
lethal and, therefore, has not been studied [43]. Together, these mixed genetic results suggest
some role of the GRK phosphorylation and β-arrestin-binding system in tolerance development,
as distinct from β-arrestin2 recruitment per se. However, given the lack of consistent effect
of β-arrestin2 knockout, and no effect of β-arrestin1 knockout [43], on opioid antinociception
and tolerance, it cannot be predicted that a lack of β-arrestin recruitment alone will enhance
antinociception and prevent tolerance. Tolerance to opioid-induced antinociception in
fact occurs in an agonist-dependent manner through multiple mechanisms [e.g., there isTrends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx 3
Voltage-gated calcium channel
(VGCC): inhibited by Gβγ subunits,
inhibiting neurotransmission.
Trends in Pharmacological Sciencessubstantial evidence for a role of a protein kinase C (PKC)-dependent process [44]], suggesting
that avoiding β-arrestin recruitment alone will not prevent antinociceptive tolerance development.
Physical dependence, commonly characterized in non-human animals by somatic withdrawal
signs, is considered a component of the formation of opioid use disorder. Opioid withdrawal
signs following chronic morphine treatment were unchanged [40] or slightly reduced at one
dose [41] in the mixed background β-arrestin2-knockout mouse (Box 2). Again, the reported
phenotype was ligand specific, because β-arrestin2 knockout did not alter oxycodone, fentanyl,
or methadone withdrawal signs [41], as well as in fact worsening morphine-induced conditioned
place preference, a model of opioid reward [45]. Despite these results, G protein bias has been
proposed as a mechanism underlying lesser dependence [2,46], or lesser reward signs, induced
by novel MOPr agonists [8,9]. AbolishedC-terminal phosphorylation sites and, therefore, β-arrestin
recruitment in the 11S/T-Amouse did not alter morphine or fentanyl withdrawal signs [23]. As such,
there is limited evidence that altered arrestin recruitment by biased MOPr agonists would prevent
physical dependence or withdrawal, or reduce addictive liability [47].
Thus, it is clear that an absolute separation of the signaling pathways leading to the analgesic ef-
fect of opioids (i.e., G protein mediated) from those producing adverse effects (i.e., β-arrestin2
mediated), as has been hypothesized (Box 1), is unlikely. Dependence, reward, constipation,
and respiratory depression, some of the most problematic effects of opioid analgesics, are not
improved in genetic models of abolished MOPr/β-arrestin interactions. There is no physiological
evidence for a putative β-arrestin2 signal mediating acute deleterious opioid effects, but a sub-
stantial body of literature demonstrates the manner in which G protein-dependent signaling me-
diates opioid effects as well as analgesia (Figure 1). Therefore, MOPr agonists biased toward G
protein signaling over β-arrestin recruitment, originally suggested to be improved analgesics,
cannot be predicted to have the previously claimed characteristics. Delineating MOPr agonist
properties that result in safe and efficacious opioid analgesia should occur via revisiting and
fully understanding the pharmacology of both existing and novel opioids, including putatively
biased ligands, and the complexity of MOPr signaling.
Current Methodological Challenges in Developing Biased MOPr Agonists
Assessment of potentially G protein-biased lead MOPr compounds has been hampered by sys-
tematically confounded signaling assays. Limitations on the dynamic range of observable effects,
such as pathway amplification and inefficiently coupled signals, have posed significant challenges
to the accurate characterization of ligand pharmacology and their relative efficacies in different
signaling endpoints.
Putatively G protein-biased compounds oliceridine [6], PZM21 [8], mitragynine pseudoindoxyl [9],
and SR170178 [7], were all initially assessed to have comparable efficacy to morphine for G pro-
tein activation. Later experiments [48–53] showed these ligands to in fact have low intrinsic
efficacy relative to morphine (Figure 2A). Importantly, highly amplified G protein assays are rela-
tively insensitive to efficacy differences between agonists due to the presence of receptor reserve
[54], causing test agonists to reach a similar maximal ‘ceiling’ of the assay, regardless of variation
in efficacy [55]. This is a straightforward pharmacological explanation for the initial description of
apparently G protein-biased MOPr compounds with low intrinsic efficacy as being highly effica-
cious for G protein activation [56].
Analyses of MOPr bias routinely compare an amplified assay of G protein activation to one
of β-arrestin recruitment [55]. In contrast to G protein signaling, β-arrestin recruitment to the MOPr
is a protein–protein interaction without amplification, measurements of which are therefore4 Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx
Box 1. The G Protein-Biased MOPr Agonism Hypothesis
G protein-biased MOPr agonists maintain the eponymous G protein signal, established to mediate analgesia, while minimizing recruitment of β-arrestin to the receptor.
MOPr/β-arrestin interactions are proposed to mediate, or to positively facilitate, deleterious opioid effects, including respiratory depression, constipation, tolerance, and
physical dependence. Therefore, MOPr agonists, which are G protein biased are hypothesized to be dramatically improved, less addictive analgesics that induce lesser
respiratory depression and constipation (Figure I). However, the initial β-arrestin2-knockout results [10,38,40] have not been repeated in later experiments [22,26,42],
while studies of mice expressing a phosphorylation-deficient mutant MOPr that does not recruit β-arrestins also do not support the G protein-biased agonist hypothesis
[23]. Furthermore, substantial evidence has accumulated for G protein mechanisms mediating respiratory depression and constipation, as well as analgesia.
The profile of apparently G protein-biased (see main text), minimally β-arrestin-recruiting lead compounds is not significantly improved over established opioids, such as
morphine [76]. The prototypical G protein-biased MOPr agonist, oliceridine (but see [51,53]), was initially reported in rodent studies to have an improved separation in
potency between antinociceptive effects and both respiratory depression and constipation [6]. Clinical trial results of this drug candidate have been mixed, with persis-
tent respiratory depression and constipation, but a marginally improved therapeutic window observed in some measures compared with morphine [3,77,78]. In regard
to abuse-related effects, volunteers rated oliceridine similarly to morphine in a drug effects questionnaire [77], and, in rodents, both the self-administration of, and the
facilitation of, intracranial self-stimulation induced by oliceridine was similar to other opioids [79,80]. Additionally, oliceridine generalized to fentanyl in a drug-discrimination
procedure, similarly to other MOPr agonists [69]. A second putatively G protein-biased compound, PZM21 (but see [48,51]), was initially reported not to induce respiratory
depression, constipation, or to be rewarding in a conditioned-place preference test in mice [8]. However, several later studies found substantial respiratory depression to be
induced by PZM21 [48,51], albeit with some variation in potency between experimenters, while the observation of minimal conditioned-place preference has been
reproduced [81]. A recent examination of the reinforcing effects of PZM21 in non-human primates showed similar abuse liability to oxycodone [82], and antinociceptive
tolerance comparable to morphine develops following prolonged treatment [48].
Recently, the G protein-bias factor of a family of newly developed compounds was correlated to the separation in potency between antinociception and respiratory de-
pression [7]. Most significantly, SR17018was reported not to induce respiratory depression [7], although again later studies have shown decreases in respiratory rate at
minimally antinociceptive doses [51]. Studies of this ligand are significantly hampered by extremely poor solubility [46,51], and a recent study reported high, DAMGO-like
arrestin recruitment by SR17018 [58].
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Figure I. Re-evaluation of G Protein-Biased μ-Opioid Receptor (MOPr) Agonist Hypothesis. (A) The G protein-biased MOPr agonist hypothesis proposes G
protein activation mediating opioid analgesia, whereas several side effects are mediated by β-arrestin2 (β-arr2). (B) Current evidence from behavioral studies in 11S/T-A
MOPr-knock-in mice, β-arrestin2-knockout mice, and direct physiological studies using regional MOPr-knockout mice and electrophysiology among other techniques
show that side effects are likely to be G protein-mediated.
Trends in Pharmacological Sciencessensitive to differences in efficacy [54]. Thus, an agonist with low intrinsic efficacy may display a
lower maximal effect relative to a high efficacy reference agonist, such as DAMGO, in a β-
arrestin assay, despite displaying the samemaximal effect in a G protein activation assay. This pat-
tern of activity stemming from the unequal comparison made between assays with different ampli-
fication leads to apparent bias of low intrinsic efficacy agonists toward G protein signalling over β-Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx 5
Box 2. Opioid Effects in β-Arrestin2-Knockout Animals
Examination of the role of β-arrestin2 in modulating, or mediating, opioid effects in vivo was stimulated by early experi-
ments on the β-arrestin2 global knockout mouse. The antinociception of morphine was observed to be dramatically en-
hanced [38], while tolerance to that effect over time was abolished [40], in this genotype when compared with wild-type
animals. This effect was ligand specific, in that there was no difference in either the acute antinociception or tolerance to
that effect induced by fentanyl, methadone, or oxycodone [39,41], or etorphine acute antinociception, between wild-type
and knockout mice. The lack of effect of β-arrestin2 knockout on fentanyl, methadone, or etorphine acute antinociception
is surprising, given that these are high-efficacy agonists that robustly induce the recruitment of β-arrestin2 to the MOPr
[7,39,51]. No mechanism underpinning the morphine-specific phenotype has yet been demonstrated, although these
results suggest that β-arrestin2 recruitment does not negatively regulate the acute antinociception of fentanyl, methadone,
or oxycodone, and is not critical for their antinociceptive tolerance.
Later experiments on the β-arrestin2-knockout mouse showed a dramatic reduction in morphine-induced respiratory
depression and constipation [10]. This observation was surprising, suggesting a positive role of β-arrestin2 in facilitating,
or mediating, opioid effects, rather than simply negatively regulating MOPr G protein activation. This led to the hypothesis
that opioid-induced respiratory depression and constipation are β-arrestin2-dependent and, therefore, that G protein-biased
agonists would reduce these effects while producing enhanced analgesia (Box 1).
The initial experiments by Bohn et al. [10,38,40,41] were performed on β-arrestin2-knockout animals with a mixed strain
background, the colony being formed from the interbreeding of knockout 129/SvJmale mice with wild-type C57BL/6 fe-
males. Inbred laboratory mouse strains vary in nociceptive responses, and a heightened antinociceptive effect of morphine
in 129/SvJ, compared with C57BL/6, mice has been demonstrated and specifically noted to be relevant to transgenic ex-
periments on mixed background animals [83]. An absence of tolerance to morphine antinociception in a related 129
mouse substrain has also been shown in multiple studies [84]. In terms of side effects, a recent study showed that the sen-
sitivity of 129 substrain animals to lethal morphine respiratory depression was lower than that of C57BL/6 mice [85]. This
evidence of strain variation in opioid response suggests that the dramatic β-arrestin2-knockout phenotype initially ob-
served was substantially confounded by parental 129/SvJ strain characteristics segregating with the knockout locus.
Therefore, it is crucial for the G protein-biased MOPr agonist proposal that these experiments are repeated on knockout
animals without a mixed strain background. Indeed, more recent work has observed minimal effects of β-arrestin2 knock-
out on opioid responses in mice congenic with the C57BL/6J strain. Neither acute antinociception in response to
morphine, oxycodone, or fentanyl, nor the subsequent development of tolerance to these drugs following prolonged
administration, was observed to be altered by β-arrestin2 knockout [42]. Similarly, experiments in multiple independent
laboratories have failed to observe any effect of the β-arrestin2-knockout genotype on morphine- or fentanyl-induced
respiratory depression or constipation [22,26]. Studies of withdrawal signs and dependence in the β-arrestin2-knockout
mouse on a C57BL/6J background have not yet been reported. The observed β-arrestin2-knockout phenotype of
enhanced morphine antinociception, alongside reduced tolerance and profoundly attenuated side effects, led directly to
the formation of the G protein-biased MOPr agonist hypothesis, but has not yet been reproduced.
Trends in Pharmacological Sciencesarrestin recruitment [55,57]. Many MOPr agonists proposed to be biased, including newly devel-
oped leads [58], as well as buprenorphine [59,60], levorphanol [61], and desmetramadol [62],
have low intrinsic efficacy relative to morphine (Figure 2A). To reiterate, the observed profile of
minimal β-arrestin recruitment, but robust G protein activation, is predictable from an understanding
of assay amplification, and is entirely consistent with multiple apparently G protein-biased MOPr
agonists having simply low intrinsic efficacy instead [51].
One solution to this confound is to compare assays with similar amplification levels. This remains
challenging but has recently been facilitated by the development of conformationally selective
nanobodies [63] and soluble miniature G proteins [64] that can be used to report receptor activa-
tion and G protein recruitment, respectively. This allows the direct comparison of agonist-induced
binding of G proteins or β-arrestin to MOPr (Figure 2B). Studies using these unamplified probes of
MOPr activation report the spectrum of agonist efficacy, confirming the partial agonism of lead
compounds oliceridine and PZM21 [51–53] (Figure 2C). Highly amplified systems can alterna-
tively be adjusted through partial receptor inactivation with irreversible antagonists, reducing
agonist maximal effect to well below the ceiling of the assay and, therefore, permitting the com-
parison of relative efficacy [54]. Efficacy as estimated through either recruitment of MOPr activa-
tion sensors or partial irreversible antagonism in a GIRK activation assay was consistent across a6 Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx
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Figure 1. Illustration of G Protein
Mediated Signaling after MOPr
Activation. Illustration of G protein-
mediated interaction after MOPr
activation. Presynaptic inhibition of
voltage-gated calcium channels (VGCC)
via Gβγ. Postsynaptic activation of
G protein coupled inwardly rectifying
potassium channel (GIRK) by Gβγ.
Analgesia and side effects are
mediated by G protein signaling.
Abbreviations: KF, Kölliker-Fuse;
PAG, periaqueductal gray; preBötC,
preBötzinger neurons.
Trends in Pharmacological Sciencesfamily of MOPr agonists [51]. It is also important to consider that β-arrestin recruitment assays
can have a limited dynamic range resulting in a ‘floor’ effect, wherein ligands below a certain
efficacy do not give a detectable response. This can be addressed by designing experimental
conditions to increase amplification, for example, by overexpression of GRK, such that all ago-
nists produce a quantifiable response (Figure 2D) [51,65]. In assays in which these amplification
confounds have been addressed, lead compounds, such as oliceridine and PZM21, as well as
buprenorphine, are not observed to be significantly G protein biased [48,51,53] (Figure 2E,F),
demonstrating that previous descriptions of biased agonism have been largely driven by system
parameters rather than by novel ligand characteristics.
Given the role of receptor phosphorylation in the development of tolerance to opioid
antinociception [23], and the limitations of β-arrestin-recruitment assays, additional descriptors
for novel ligands are needed, such as phosphorylation site analysis. GRK recruitment to the active
MOPr and subsequent phosphorylation are the usual prerequisites for β-arrestin binding [24]. The
pattern of phosphorylation induced by agonist treatment varies between high-efficacy agonists,
such as DAMGO, which induce phosphorylation at multiple sites, and lower efficacy agonists,
such as morphine [66], which have a more restricted phosphorylation pattern [24]. Generally,
putatively biased agonists with low efficacy for G protein activation follow this pattern, with the
exception of SR17018, which, surprisingly, has been shown to induce DAMGO-like multisite
phosphorylation [51].
The observations outlined earlier should prompt a re-evaluation of the pharmacological charac-
teristics of proposed biased opioids. At present, experimental methods have been inconsistent
between studies, making a systematic evaluation of efficacy and, therefore, bias, challenging.
Accurate, clear quantification of intrinsic efficacy is necessary to enable robust comparison of
agonists and any potential bias. Empirical measurements of ligand activity, such as agonistTrends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx 7
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Figure 2. G Protein-biased Agonists have Low Intrinsic Efficacy. (A) Low intrinsic efficacy of putatively biased μ-opioid receptor (MOPr) agonists, reanalyzed from
published data as previously described [51]. Y-axis shows operational efficacy, τ, of each agonist as a percentage of morphine efficacy within that assay. (B) Comparison of
G protein to β-arrestin2 binding is a robust test of potential G protein-biased MOPr agonism. This was recently facilitated by the development of soluble, ‘miniature’ G
proteins (mini-Gsi), which can be used to assay MOPr activation (C), and then compared with β-arrestin2 recruitment (D). Maximum effect (E) and potency (F) of these
agonists is consistent between the two assays, which have comparable levels of amplification. See [8,48,51,52,56,65,66]. Data on mini-Gsi and β-arrestin2 recruitment
reproduced from [51]. All data shown as mean, with bars representing standard error of the mean.
Trends in Pharmacological Sciencesmaximal effect and potency, allow quantification without making mechanistic assumptions about
the receptor system [56,67]. Maximal effect and potency can be directly compared
between assays (Figure 2E,F). Bias plots of ligand activity between two assays use untrans-
formed data to highlight differences in system amplification and show the extent to which ago-
nists may vary in activity across signaling pathways [2]. The combination of these simple
analyses with assays optimized to avoid systematic confounds allows assessment of potential
agonist bias in a rigorous manner (Figure 2E,F and Box 3). Deviations from the profile of a family
of reference compounds should then reveal potential biased agonism.
The fact that most putative G protein-biased MOPr ligands described to date have been low
efficacy agonists (Figure 2A), together with challenges to the ‘β-arrestin2 hypothesis’, brings8 Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx
Box 3. Designing Assays for Evaluation of Opioid Ligands
Several factors should be accounted for in the systematic design of signaling assays to capture the full range of MOPr ag-
onist efficacy. Consideration of these factors should allow analysis of potential ligand bias in a manner not confounded by
system amplification or kinetics of effect.
Reference Ligands
The consistent use of multiple reference ligands that span a large efficacy range is a helpful strategy that facilitates the de-
tection of ceiling (amplification) and floor (underamplification) effect confounds [56]. High-efficacy agonists DAMGOormet-
enkephalin will define the maximum possible effect in most assays. The partial agonist morphine is an essential reference
that allows for the detection of system confounds. If possible, another agonist known to be low efficacy, such as
oliceridine, should also be used. If the maximum effect reached by morphine and/or oliceridine is similar to DAMGO, the
amplification of the assay is very high and due to receptor reserve, will not be sensitive even to dramatic efficacy differ-
ences. Similarly, if the low efficacy agonists do not produce substantial, measurable effects that can be fitted to a curve,
underamplification will confound any estimate of relative efficacy, potency, or agonist bias.
Probe Ligands
Considerations such as the active concentration range and whether maximal effect concentrations can be reached within
the solubility range are key for an accurate description of the pharmacology of a ligand. If practical, half-log unit increments
in concentration are recommended to obtain more accurate potency estimates. This is particularly important for low-
efficacy agonists that give weak responses in poorly coupled assays.
Assay Amplification
It is important to assess each assay for relative levels of system amplification. This can be done using reference com-
pounds with known low intrinsic efficacy as suggested earlier, for example, morphine and oliceridine. When a possible ceil-
ing effect is observed, this can be controlled by adjusting relative expression of receptor and/or reporter, or considering
irreversible antagonism/receptor inactivation. Underamplification can be adjusted by ensuring all probe agonists reach sig-
nificant effect compared with vehicle, such that maximal effect and potency estimates can be made. Again, modification of
receptor and reporter expression and consideration of ‘bottlenecks’, such as low GRK expression in β-arrestin-recruit-
ment assays, will ensure optimized assay conditions.
Assay and Ligand-Binding Kinetics
Given that divergent kinetics of effect can alter the apparent bias profile [86], it is important to make real-time measurements
to ensure a maximum effect is being captured for all agonists. When real-time measurements are not possible, variations in
agonist-incubation time-courses are recommended. Additionally, it is important to consider how agonist efficacy and ligand
binding kinetics may interact to alter apparent potency and maximal effect.
Analysis
A consistent analysis workflow is important for reproducible pharmacological descriptions of ligands: (i) fit simple concentra-
tion–response curves to the mean of replicates within each experimental day. If the curve is atypical (e.g., steep or two-phase)
conduct robust statistical test comparing fits, for instance an extra sum-of-squares test, to check if more complex model is
preferred; (ii) average maximal effect and potency from each separate experiment. Compare rank order across assays, for in-
stance via simple scatter plot. Inspect for outliers compared with reference ligands; (iii) construct bias plots (showing the relative
efficacy of a given concentration of a drug in two different assays) to visualize both assay amplification differences (skewing all
curves toward one assay) and divergent agonists (potential biased agonism); and (iv) if desired,maximal effect can be converted
to operational efficacy directly (Emax of test/Emax of reference = τ/[1+τ]) when assay overamplification is not a confound.
Identification of Biased Agonists
Biased agonists will diverge from a family of reference compounds, in terms of potency, as shown in a bias plot or rank
order of maximal effect. The magnitude of biased agonism should be considered alongside its presence or absence, for
instance via the widely used transduction coefficient, or by subtraction of maximal effect.
Trends in Pharmacological Sciencesinto question to what extent the profile of the ligands investigated (Box 1) can be explained by
partial agonism rather than by ligand bias. While agonists proposed to be biased certainly pro-
duce significant respiratory depression (Box 1), there may be marginal improvements in the ther-
apeutic window arising from the low efficacy of these compounds [51]. The existing opioid
analgesic buprenorphine, which has extremely low intrinsic efficacy, has been noted to have a
plateau of effect on respiration [68], contributing to reduced overdose risk. A recent study ofTrends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx 9
Outstanding Questions
Are MOPr agonists biased between
different G protein subtypes or effectors
downstream of G protein activation?
Are MOPr agonists biased between
the engagement of different GRKs
and/or PKC isoforms?
Are there other unappreciated signaling
events that are differentially engaged
upon MOPr activation by different
agonists?
Howdoes the recruitment ofβ-arrestins
modulate MOPr activity in vivo?
How do the multiple systems of MOPr
regulation (GRKs, β-arrestins, PKC iso-
forms, and internalization machinery)
interact in the development of tolerance
and dependence?
How does tolerance development to
distinct opioid-mediated physiological
effects, such as analgesia and respira-
tory depression, differ depending on
the opioid agonist?
Can biased agonists differentially
induce tolerance between two different
physiological opioid effects?
Do β-arrestins mediate a yet to be dis-
covered G protein-independent signal
in nervous tissue with a physiological
outcome?
Does extremely low agonist efficacy
consistently reduce opioid-induced re-
spiratory depression? To what extent
is it possible to improve MOPr agonist
analgesics via manipulation of intrinsic
efficacy?
Might there be a MOPr agonist with
high, DAMGO-like G protein efficacy
and significantly less β-arrestin recruit-
ment than would be predicted from
that efficacy?
What are the efficacy requirements for
the various responses to opioids in
different tissues?
What is the effect of species difference
on opioid signaling and behavior?
Trends in Pharmacological Sciencesclinically used opioids found that intrinsic efficacy, rather than any G protein/β-arrestin bias, pre-
dicted the rate of reported adverse events [65]. This suggests a route toward opioid analgesics
with reduced respiratory burden, and is a plausible counter explanation for the slightly improved
profile of some apparently biased MOPr agonists. The reduced efficacy of oliceridine and
PZM21, while not as low as that of buprenorphine (Figure 2A,E) [51], might explain the observed
preclinical and clinical profile of these ligands. Additional studies are required to connect specific
signaling profiles to behavioral effects. Recent work has applied fixed agonist:antagonist ratios to
determine the efficacy requirements of in vivo opioid agonist effects [69,70]. Using this methodol-
ogy may resolve the contribution of in vitro signaling profiles, alongside ligand pharmacokinetics,
bias, and off-target interactions, to MOPr agonist behavioral effects.
Several studies have observed some MOPr agonists to be substantially biased when amplification
confounds are addressed. Notably, the peptide endomorphin 2 has been described as β-arrestin-
biased following characterization of efficacy using irreversible antagonism, with comparable
β-arrestin recruitment to Met-enkephalin but lesser efficacy for G protein activation [71,72]. Another
peptide, bilorphin, displays reduced β-arrestin2 recruitment but similar G protein efficacy tomorphine,
again as described using irreversible antagonism [71]. However, testing the physiological effect of
biased MOPr agonism in animal models will require development of brain-penetrant agonists con-
sistently and rigorously described to retain their bias toward or away from β-arrestin recruitment.
Concluding Remarks
G protein-biased agonists of MOPr have been widely asserted to constitute a novel and
substantially improved class of analgesics. The hypothesis underlying this, being that MOPr
coupling to β-arrestin2 mediates deleterious opioid effects, including respiratory depression,
constipation, dependence, and withdrawal, has been recently challenged. First, a recent study
was unable to repeat initial results in the β-arrestin2-knockout mice. Second, a genetic model of
reduced MOPr/β-arrestin interactions, the 11S/T-A mouse, does not support a role of β-arrestin
recruitment in mediating or facilitating these effects. Third, physiological studies show the manner
in which well-established MOPr G protein-signaling mechanisms cause analgesia, respiratory
depression, and constipation (Figure 1). As such, current evidence does not support the proposal
that the absence or reduction of β-arrestin2 recruitment to the MOPr by drug candidates (i.e., G
protein-biased agonism) would improve the in vivo profile of opioid analgesics (Box 1 and Figure 1)
Furthermore, re-evaluation of lead compounds that have been proposed to be G protein biased
has led to the recognition of the low intrinsic efficacy of these compounds relative to morphine
(Figure 2A). This factor, together with amplification confounds, has led to activity typical of partial
agonists being described as apparent biased agonism away from β-arrestin recruitment. Very low
efficacy MOPr agonists continue to be proposed to be G protein-biased (e.g., [58]) from con-
founded assay results. The extent to which these newly developed ligands, such as the drug can-
didate oliceridine, constitute substantially G protein-biased MOPr agonists is under question.
Certainly, it appears that no MOPr agonist has yet been identified with high, DAMGO-like G pro-
tein efficacy and substantially less β-arrestin recruitment than would be predicted from that
efficacy.
The measurement of β-arrestin recruitment to the MOPr in model cell systems has proven to be
robust and amenable to high-throughput screening. However, the identification of β-arrestin-
dependent MOPr-signaling pathways in neurons and their role in controlling the physiological
effects of opioids is still necessary to understand the potential impact of biased MOPr agonism.
The most widely proposed β-arrestin-dependent MOPr signal is activation of ERK/MAPK, but
this is at least partly also G protein dependent [73]. The concept of β-arrestin-dependent10 Trends in Pharmacological Sciences, Month 2020, Vol. xx, No. xx
Trends in Pharmacological Sciencessignaling has recently been challenged at related GPCRs via genetic deletion of G proteins
[74,75]. A specific physiological effect of MOPr-signaling events dependent on β-arrestin recruit-
ment has not, to date, been shown in relevant tissue. Future studies linking in vitro signaling
events to in vivo behavior would benefit from physiological experiments across species, including
rodents and non-human primates, because MOPr agonist effects, including antinociception and
lethality, vary substantially from the most common model species, mice, to other rodents and to
primates.
In regard to the theoretical effect of an extremely G protein-biased opioid ligand, while acute side
effects and withdrawal are not predicted to be reduced, tolerance to opioid antinociceptive effect
may be altered. The extent to which agonists can be designed that avoid C-terminal phosphoryla-
tion remains to be seen, as does how additional systems might interact with the primary desensiti-
zation pathway in this case. Multiple interacting pathways contribute to tolerance to opioid
antinociception. Tolerance to opioid effects, such as respiratory depression and constipation,
develops via similar systems, although how tolerance to opioid effects may differ for G protein or
β-arrestin-biased agonists has not yet been resolved (see Outstanding Questions).
Recent data have challenged the relationship between MOPr/β-arrestin recruitment and opioid-
induced side effects. We encourage a critical re-evaluation of descriptions of biased agonism at
the MOPr that takes into consideration the confounding factors that have led to confusion in the
opioid field. With the toolbox of opioid agonists and assays continuing to expand, there is a clear
opportunity to understand the pharmacological and signaling characteristics that dictate the
physiological effects of these opioid ligands, with a view to improved analgesics (see Outstanding
Questions). However, this will only be possible through systematic and consistent characterizations
of novel compounds.
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